MedTrace Logo

EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer

NCT03542799 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-05-31

No results posted yet for this study

Summary

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.

Conditions

Interventions

BIOLOGICAL

EGFR IL12 CART

EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)

Sponsors & Collaborators

  • The Pregene (ShenZhen) Biotechnology Company, Ltd.

    collaborator INDUSTRY

  • Shenzhen Second People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2020-05-23
Completion
2021-05-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542799 on ClinicalTrials.gov